根治性前列腺切除术时发现淋巴结转移男性的当代治疗模式与结局
利用美国国家癌症数据库纳入7791例根治性前列腺切除术后病理淋巴结阳性(pN1)前列腺癌男性,描述术后初始治疗模式及总生存。术后63%观察、20%单纯雄激素剥夺治疗、5%单纯放疗、13%雄激素剥夺治疗联合放疗。联合雄激素剥夺治疗与放疗较观察与更好的总生存相关(多变量HR 0.69,95%CI 0.52-0.92,p=0.010)。
要点
- 术后初始治疗以观察为主(63%),雄激素剥夺治疗联合放疗占13%。
- 分级分组4-5、pT3b-T4、切缘阳性及阳性淋巴结数更多为更差总生存的独立预测因素。
- 联合雄激素剥夺治疗与放疗较观察与更好总生存相关(HR 0.69,95%CI 0.52-0.92,p=0.010)。
核心结论
- 患者和肿瘤特征与pN1前列腺癌根治性前列腺切除术后治疗策略选择及生存相关。
- 多模式治疗可能对该患者人群有益。
研究设计与样本
- 使用美国国家癌症数据库识别7791例根治性前列腺切除术时发现淋巴结转移的男性。
- 采用多项逻辑回归和Cox比例风险回归分别识别与术后管理策略选择和总生存相关的患者、肿瘤及机构特征。
主要发现
- 术后初始管理为观察者占63%,单纯雄激素剥夺治疗占20%,单纯放疗占5%,雄激素剥夺治疗联合放疗占13%。
- 较年轻年龄、较低合并症负担、更高分级和分期及阳性手术切缘与接受联合治疗的可能性更高相关。
- 分级分组4-5疾病、pT3b-T4疾病、阳性手术切缘及阳性淋巴结数更多为更差总生存的独立预测因素。
- 随着不良预后因素数量增加,校正后10年总生存概率从84%降至32%。
- 联合雄激素剥夺治疗与放疗较观察与更好总生存相关(多变量HR 0.69,95%CI 0.52-0.92,p=0.010)。
关键数值与推荐
- 术后初始管理:观察63%,单纯雄激素剥夺治疗20%,单纯放疗5%,雄激素剥夺治疗联合放疗13%。
- 联合雄激素剥夺治疗与放疗 vs 观察的总生存多变量HR 0.69(95%CI 0.52-0.92,p=0.010)。
- 校正后10年总生存概率随不良预后因素数量增加从84%降至32%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: A thorough understanding of the natural history and consensus regarding the optimal management of pathological lymph node positive (pN1) prostate cancer are lacking. Our objective was to describe patterns of care and outcomes of a contemporary cohort of men with pN1 prostate cancer. MATERIALS AND METHODS: We used the National Cancer Database to identify 7,791 men who were found to have lymph node metastases at radical prostatectomy. Multinomial logistic regression and Cox proportional hazards regression were used to identify patient, tumor and facility characteristics associated with the choice of management strategy after radical prostatectomy and overall survival, respectively. RESULTS: Initial post-prostatectomy management was observation in 63% of the men, androgen deprivation therapy alone in 20%, radiation therapy alone in 5%, and androgen deprivation therapy and radiation therapy in 13%. Younger age, lower comorbidity burden, higher grade and stage, and positive surgical margins were associated with a higher likelihood of receiving combination therapy. Grade group 4-5 disease, pT3b-T4 disease, positive surgical margins and a higher number of positive lymph nodes were independent predictors of worse overall survival. The adjusted 10-year overall survival probability decreased from 84% to 32% with the presence of an increasing number of adverse prognostic factors. Treatment with combined androgen deprivation therapy and radiation therapy was associated with better overall survival (multivariable HR 0.69, 95% CI 0.52-0.92, p = 0.010 for combination therapy vs observation). CONCLUSIONS: Patient and tumor characteristics are associated with the choice of management strategy after radical prostatectomy and survival in men with pN1 prostate cancer. Multimodal therapy may be of benefit in this patient population.
引用
- Zareba P, Eastham J, Scardino PT, et al. Contemporary Patterns of Care and Outcomes of Men Found to Have Lymph Node Metastases at the Time of Radical Prostatectomy. J Urol. 2017. PMID: 28625507. doi:10.1016/j.juro.2017.06.062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。